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Dr. Maltais manuscript (1) is a nice overview touching every 
major aspect regarding the strategy and the most important 
steps of less invasive left ventricular assist device (LVAD) 
implantation. This work gives an answer to the question 
why centers with very good results following LVAD 
implantation through a conventional sternotomy approach 
should adopt less invasive strategies when implanting 
second and third generation continuous flow devices as 
outlined in the Vanderbilt paper.
Mitral and/or tricuspid valve surgery are among the 
most common cardiac procedures which are increasingly 
performed through less invasive thoracotomy incisions to 
avoid sternotomy. Several randomized controlled studies 
have demonstrated excellent results that equal those of 
“larger incision” methods. Less invasive approaches for 
valve reconstruction and replacement surgery prove to 
be beneficial for several perioperative factors including 
bleeding, blood transfusion, ventilation time and hospital 
stay. Nonetheless open chest procedures remain the gold 
standard for valve surgery and no randomized study has yet 
been able to show a benefit of less invasive approaches for 
early mortality (2). 
If one looks at the introduction of less invasive surgery 
for LVAD implantation, one may appreciate that the overall 
approach and development of the technique is quite similar 
to that used for mitral valve surgery: “How to do papers”, 
reports about single cases and small non-randomized studies 
have been published about initial experiences, showing 
that less invasive approaches for LVAD implantation are 
feasible and can be effectively implemented to become a 
standard procedure. These articles were followed by papers 
reporting on small cohorts that showed a reduced incidence 
of bleeding, less need for blood transfusion, less respiratory 
morbidity and right ventricular failure (RVF) (3). Following 
all these reports, randomized studies are yet necessary 
to confirm that it is the less invasive approach itself that 
contributed to these favourable results. Benefits of this 
approach will need formal evaluation of efficacy and require 
controlled studies, preferably randomized. 
Even though similar at the first glance, the second 
analysis of these two fields of application reveals significant 
differences. Although some clinical benefits are substantial, 
the main driving force behind less invasive approaches in 
cardiac valve surgery is still cosmetic issues, costs, and the 
aim to compete with percutaneous approaches feasible for 
interventional cardiology treatment. Sometimes, patients 
are reluctant to undergo a sternotomy while still being 
asymptomatic (4,5).
However, all these thoughts and factors have absolutely 
nothing to do with LVAD surgery: patients who need an 
assist device are terminal heart failure patients and therefore 
extremely symptomatic. They usually just want to survive 
and will never ask for smaller incisions. In addition there are 
no percutaneous alternatives and patients are not afraid of 
sternotomy: they will rarely demand for cosmetically sound 
solutions, as their only alternative is death.
Among multiple potential problems, three of them 
represent real challenges for every VAD team because 
they are strong predictors of outcome and survival: RVF, 
cerebrovascular accident and the need for reoperation. 
Although the authors have already roughly covered these 
areas, we would like to shortly add a few comments as we 
believe that by beneficially influencing these aspects, the 
less invasive approach in VAD surgery has the potential to 
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become a match-changer, when not a match-winner.
Right ventricular failure (RVF)
Newer generat ion cont inuous-f low LVADs have 
contributed to improve outcomes with lower incidence of 
immediate and mid-term RVF when compared with the 
pulsatile devices. Yet, RVF still occurs in 9% to 40% of 
LVAD recipients. Postoperative RVF is associated with 
poor outcomes, end-organ dysfunction, high mortality and 
reduced survival to transplant (6).
Less invasive approach may lead to less RV dysfunction. 
Several experimental and clinical studies show that an intact 
pericardium preserves the right ventricular function. Once 
the pericardium is incised right ventricular contractility has 
been shown to decrease and the physiologic response to 
changes in afterload and preload decreases. 
Keeping the pericardium closed, the minimal invasive 
approach seems to protect the right ventricle from 
postoperative dilatation. Less bleeding and subsequent 
need for transfusion may further protect the right ventricle 
and the lungs (7,8). On the other side, if RVF occurs in the 
setting of less invasive LVAD implantation, access to the 
right heart is not possible and percutaneous ECMO would 
be the only solution.
Cerebrovascular accidents
Despite improved technology and different anti-coagulation 
strategies, stroke remains a significant complication 
following LVAD implantation. In the original randomized 
controlled trial of continuous flow-LVADs, the incidence 
of stroke (hemorrhagic and ischemic) was 18% at 2 years 
of follow-up. The Fifth Interagency Registry for 
Mechanically Assisted Circulatory Support (INTERMACS) 
annual report had a nearly identical incidence with 17% 
stroke at 2 years (9,10). In this context Maltais et al. 
mention different sites for implantation of the outflow graft 
especially in patients with porcelain aorta and in those with 
proximal bypass graft anastomoses. Very recent reports 
from Riebandt et al. show that routine implantation of the 
outflow graft into the subclavian artery can reduce the rate 
of embolization into the carotid arteries. This approach 
may reduce the overall ischemic cerebrovascular event 
rate, as the first two aortic branches are protected from 
the ascension of possible thrombotic material into cerebral 
vessels. Furthermore, technical advantages are the relative 
ease of surgical exposure of the subclavian artery and the 
fact that it is usually free from atherosclerosis. 
Concerns about this technique are the compression 
of the outflow graft by the surrounding structures, excessive 
blood flow to the arm as well as flow disturbances on 
extensive elevation of the arm. Banding of the subclavian 
artery is mandatory if there is a mean pressure difference 
of more than 20 mmHg to avoid excessive blood flow to the 
arm (11).
Reoperations
Patients who receive LVAD as a bridge to transplantation 
will need reoperation for transplantation. Every surgeon 
who has performed transplantation in patients with 
previously implanted LVAD knows that pericardial 
adhesions and re-sternotomy is challenging and may 
increase morbidity and mortality of the second intervention. 
This observation has already been confirmed for redo valve 
surgery (12). 
When initial surgery is performed through right mini-
thoracotomy or small left subcostal incision, opening 
the sternum is considerably facilitated and the technical 
challenges of the second procedure are reduced: there is 
minimal to absent danger of heart injury, there are less 
adhesions, which means less postoperative bleeding and 
therefore less need for postoperative transfusion. This again 
positively influences the lung function and the recovery of 
the right ventricle of the transplanted heart.
Even patients that are not scheduled for subsequent 
transplantation may benefit from the reduced trauma due 
to a less invasive intervention. Should pump failure 
happen or drive line damage which is more likely to occur 
in patients on support for several years, the less invasive 
approach through thoracotomy will facilitate straight-
forward pump exchange in case of pump thrombus 
formation or driveline fractures. This means that the less 
invasive implantation technique may also be attractive in 
destination patients.
There are two additional aspects that we would like to 
add to this discussion and which should be considered as 
words of caution. A strategy to perform less invasive LVAD 
implantation should not compromise the completeness 
of therapy and safety. This concerns the requirement for 
concomitant coronary circulation tricuspid and mitral valve 
repair (MVR) and off-pump surgery.
The function of the right ventricle is one of the limiting 
factors in long-term survival of destination patients. Many 
patients require LVAD support for longer periods of time 
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(prolonged waiting time until transplantation and increasing 
application of destination therapy) and the presence of 
severe tricuspid valve regurgitation has been demonstrated 
to be likely associated with increased midterm morbidity 
and mortality. We favor, even in the absence of evidence-
based data, reconstruction of the tricuspid valve with ring 
annuloplasty as soon as regurgitation is moderate to severe. 
There are at least theoretical short- and long-term benefits 
when tricuspid valve regurgitation is addressed. Elimination 
of tricuspid regurgitation may lead to improvement rather 
than worsening of the RV function and reducing venous 
congestion may improve hepatic and renal perfusion (13,14).
In patients bridged to transplantation, there are reports 
that concomitant MVR during implantation of continuous-
flow LVAD may further decrease pulmonary vascular 
resistance more than after LVAD implantation alone. This 
may permit certain patients found to be ineligible for 
transplantation to become candidates after a certain period 
of LVAD support (15).
As concomitant valve procedures to LVAD implantation 
usually require full sternotomy, the threshold for addressing 
the valves should not change!
Secondly, we do not support the concept of implanting 
LVADs off-pump. Even in patients undergoing assist device 
implantation under full sternotomy we would refrain from off-
pump procedures. Short period of asystolie with the help of 
adenosine as reported in the Vanderbilt strategy (1) or rapid 
pacing during outflow graft connection may lead to passive 
dilation of the right ventricle which may be deleterious in 
patients with borderline preoperative RV-function. Sutures 
can also easily tear through thin myocardium when the 
sewing ring is attached to a beating and volume-loaded 
heart. In general, operation through a limited incision 
leaves fewer margins for error and options to deal with 
problems and complications are less confortable when 
LVAD implantation is performed off-pump.
To benefit from the versatility of cardiopulmonary bypass 
and to reduce surface trauma, the use of an ECMO system 
may be beneficial.
We congratulate Dr. Maltais and his team for their work. 
The Vanderbilt strategy clearly shows the need for refining 
and further developing minimal and alternative approaches. 
This is of actual interest with the upcoming generation of 
smaller devices. Although less invasive LVAD implantation 
may have the potential to develop into a gold standard, 
initial steps should be cautious and never compromise 
results of a good working LVAD program.
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